Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tsRNA-DC vaccine
- Development stage
- Preclinical
- Lead developer
- Nanjing Medical University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous, Intradermal
01
Overview
The tsRNA-DC vaccine is an experimental immunotherapy platform that utilizes tRNA-derived small RNAs (tsRNAs) to modulate or prime dendritic cells (DCs) for therapeutic purposes, primarily in oncology. tsRNAs are a class of small non-coding RNAs generated by the specific cleavage of precursor or mature tRNAs. In this vaccine approach, autologous or allogeneic dendritic cells are loaded with specific tsRNAs that can either serve as antigens or act as regulatory molecules to enhance DC maturation, antigen presentation, and the subsequent activation of cytotoxic T lymphocytes (CTLs). Preclinical studies have demonstrated that tsRNA-pulsed DCs can effectively trigger systemic immune responses against tumor-specific targets, making it a novel candidate in the field of RNA-based cell therapies.
- Other names
- tRNA-derived small RNA-pulsed dendritic cell vaccinetsRNA-pulsed DC vaccine
02
Targets
PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on tsRNA-DC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tsRNA-DC vaccine.